StockpollyBeta
Get App
Popularity #2,700
DSGN · NASDAQ · Biotechnology

Design Therapeutics (DSGN)

Develops GeneTAC small molecules that tune disease-causing gene expression.

$12.34
vs last close−0.82 (−6.23%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue0000000015−1500
Gross profit00000000−151500
19151415161720215332022
Research & development131110101212151615131416
645545565556
Selling & marketing000000000000
General & administrative645445565556
Other expenses00000000−151500
Operating income−19−15−14−15−16−17−20−22−19−18−20−22
333333322222
Interest income000003322222
Other non-operating income0−3−3−3−3−3−3−2−2−2−20
Income before tax−16−12−11−12−13−14−18−19−17−16−18−20
Net income from continuing operations−16−12−11−12−13−14−18−19−17−16−18−20
Net income−16−12−11−12−13−14−18−19−17−16−18−20
EPS, basic−$0.28−$0.21−$0.20−$0.21−$0.23−$0.24−$0.31−$0.34−$0.30−$0.27−$0.29−$0.32
EPS, diluted−$0.28−$0.21−$0.20−$0.21−$0.23−$0.24−$0.31−$0.34−$0.30−$0.27−$0.29−$0.32
Weighted average shares, basic565656575757575757576163
Weighted average shares, diluted565656575757575757576163
EBITDA−19−12−11−12−13−14−18−19−17−16−17−22
Depreciation & amortization000000000000
EBIT−19−12−11−12−13−14−18−19−17−16−18−22